CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 6 3
Pages: 1  2  
Next
Foreword 

AIDS-related Kaposi's Sarcoma: Options for Today and Tomorrow

By

Bijan Safai, MD, DSc
Department of Dermatology, New York Medical College, Valhalla

| June 2, 1996

Prior to 1981, Kaposi sarcoma (KS) was considered a rare human cancer occurring primarily among elderly Italian and Jewish men of eastern European ancestry. I wrote a review of KS research and clinical experiences that appeared in CA: A Cancer Journal for Clinicians. Publication of this article in January 1981 coincided with a dramatic upsurge in the number of cases of KS in young homosexual males reported to the Centers for Disease Control. The general lack of information about this disease was readily apparent when, upon publication of this article, my office was inundated with calls from physicians requesting additional information on this disease. Later on it was recognized that KS among young homosexual men was actually part of the clinical syndrome seen in the epidemic of acquired immune deficiency syndrome (AIDS).

The body of clinical experience with AIDS-related KS has grown significantly over the past 15 years. This experience has led to a greater understanding of the pathogenesis of KS in general, and angiogenesis and tumor growth factors in particular, and to the establishment of protocols for treating patients with AIDS-related KS. Now, physicians can usually diagnose this disease on a clinical basis, and pathologists can diagnose it with certainty on histologic grounds.

The purpose of this symposium was to review our experience with KS in patients with AIDS and to provide an update on KS epidemiology, pathology, and clinical presentation in AIDS patients. Current treatment options were discussed, as well as treatment modalities that are expected to be available in the near future.

The Epidemiologic Scope of Kaposi's Sarcoma

Worldwide, there are four clinical presentations of KS--the classic form, the African form, the form observed in transplant patients who are immunocompromised as a result of immunosuppressive drug therapy, and the AIDS form. Dr. Haverkos discusses in detail differences in the epidemiology and clinical presentation of these four forms of KS. Data suggest that the cause of AIDS-related KS is multifactorial. In addition to HIV infection, it has been hypothesized that necessary or enhancing cofactors associated with the development of this form of KS may include a genetic predisposition, the use of nitrite inhalants, a second sexually transmitted agent, or a fecal/oral agent. Dr. Haverkos supports this hypothesis using comprehensive epidemiologic data from the Centers for Disease Control and his own extensive research.

Clinical Manifestations of Kaposi's Sarcoma

In my presentation I discuss the clinical manifestations of KS. We have proposed that the etiologic factor responsible for KS is immune dysregulation, rather than immune deficiency. Epidemiologic data further suggest that the homosexual life-style contributes to conditions necessary for the development of this form of KS. The sexually transmissible cytomegalovirus and human papillomaviruses have been implicated in particular. Also implicated are the potentially mutagenic drugs, such as nitrite inhalants, that are frequently abused by AIDS patients prior to their becoming ill.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy